Venus Remedies Ltd. News and Updates

Name: Latest research reports of Venus Remedies Ltd. authored by Keynotes Financial Opiniery and published by - Trendlyne research reports.
Item: Venus Remedies Ltd.
Rating: 5
Author: Keynotes Financial Opiniery

Keep track of all breaking news on Venus Remedies Ltd. from all sources in a single place.

Load latest

Venus Remedies Ltd.

28 Aug 2023

453.95

3.16%

Venus Remedies gains 5% on Saudi Arabia's marketing approval for anti-coagulant drug

Moneycontrol

The company has said it has so far secured marketing authorisations from Saudi Arabia for six antibiotics meant for intensive care units and three oncology products

Venus Remedies Ltd.'s price crossed above 30Day SMA today

Venus Remedies shares up on Saudi Arabia's approval for Enoxaparin

Business Line | 28 Aug 2023

Venus Remedies Ltd.

16 Aug 2023

453.95

3.16%

Indian Pharmaceutical company

Buy: Venus Remedies Ltd.

Keynotes Financial Opiniery

The Indian pharmaceutical and healthcare sector is anticipated to register a growth of 8-10% in FY24. Pharmaceutical businesses will continue to reassess the risk of their dependencies on global supply chains, given the resurfacing of the COVID-19 pandemic in some nations and the recent Russia-Ukraine war that has significantly impacted the operations of pharmaceutical companies globally.

Venus Remedies Ltd. is trading above its 200 day SMA of 380.1

Venus Remedies Ltd.

31 Jul 2023, 11:53AM

453.95

3.16%

Venus Remedies gets market authorisations for cancer drugs from Philippines, Praguay, Georgia, Moldova

Moneycontrol

With this, the company has secured 506 marketing approvals for its oncology products across 76 countries.

Venus Remedies Ltd. has gained 51.59% in the last 6 Months

Venus Remedies Ltd.

05 Jul 2023

453.95

3.16%

Venus Remedies jumps 3% on nod to operate in 4 foreign markets

Moneycontrol

The company has secured 503 marketing approvals for its oncology products across 75 countries.

Venus Remedies Ltd. has gained 51.59% in the last 6 Months

Venus Remedies gets marketing approval from different countries for chemotherapy drugs

Moneycontrol | 05 Jul 2023

Venus Remedies Ltd.

22 Jun 2023

453.95

3.16%

Venus Remedies shares locked at 5% upper circuit as German arm gets Spanish regulator nod to market Meropenem in Spain

livemint

Venus Remedies' German subsidiary Venus Pharma GmbH has received this approval for 500mg, 1g and 2g injections of this last-recourse antibiotic.

Venus Remedies Ltd. is trading above its 200 day SMA of 380.1

Venus Remedies hits 5% upper circuit on drug approval in Spain

Moneycontrol | 22 Jun 2023

Venus Remedies Ltd.

07 Jun 2023

453.95

3.16%

Venus Remedies share price gains on GMP Certification from Ukraine

Moneycontrol

The share touched a 52-week high of Rs 263.55 and a 52-week low of Rs 145 on May 31, 2023 and February 8, 2023, respectively.

Venus Remedies Ltd.'s price crossed above 100Day SMA today

Venus Remedies gets GMP certification from Ukraine for Carbapenem, oncology facilities in HP

Moneycontrol | 07 Jun 2023

Venus Remedies Ltd.

01 Jun 2023, 11:52AM

453.95

3.16%

Venus Remedies gets marketing authorization from Saudi Arabia for chemotherapy drug Docetaxel

Moneycontrol

The development comes three months after the company received good manufacturing practices (GMP) certification from the Saudi Food and Drug Authority (SFDA) for all its production facilities at its unit in Baddi, Himachal Pradesh.

Venus Remedies Ltd. is trading above its 200 day SMA of 380.1

Venus Remedies Ltd.

30 May 2023, 09:54AM

453.95

3.16%

Venus Remedies hits 20% upper circuit after March quarter net profit jumps 200%

Moneycontrol

Standalone net profit for the March quarter stood at Rs 7.54 crore, up 211.57 percent from Rs 2.42 crore a year ago. Revenue for the quarter rose 15.34 percent to Rs 148.53 crore last year.

Venus Remedies Ltd. is trading above its 200 day SMA of 380.1

Venus Remedies Ltd.

23 May 2023

453.95

3.16%

Venus Remedies gets GMP certification from Kenya for production facilities in Baddi

Moneycontrol

The Pharmacy and Poisons Board (PPB) of the Kenyan Health Ministry granted the certification following a rigorous audit of the company's production facilities in Baddi, a company statement said.

Venus Remedies Ltd. is trading below its 30 day SMA of 459.4

Venus Remedies Ltd.

27 Feb 2023

453.95

3.16%

Venus Remedies gains on Saudi certification to all production units in Baddi

Moneycontrol

The certification is a testament to the company's commitment to maintaining high-quality standards in its manufacturing processes, which will help it expand its presence in the Saudi Arabian market, Venus Remedies said.

Venus Remedies Ltd. is trading above its 200 day SMA of 380.1

Is Venus Remedies Ltd. worth buying?

67 Votes:

Buy 74.63%

Sell 16.42%

Hold 8.96%

67.97% Gain from 52W Low

Venus Remedies Ltd. News and Updates

Keep track of all breaking news on Venus Remedies Ltd. from all sources in a single place.